Cardiff Oncology (CRDF)
(Real Time Quote from BATS)
$2.46 USD
-0.01 (-0.41%)
Updated Oct 2, 2024 09:46 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Cardiff Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -41.44 | -38.70 | -28.29 | -19.31 | -16.41 |
Depreciation/Amortization & Depletion | -0.52 | 0.87 | 2.06 | 0.47 | 0.49 |
Net Change from Assets/Liabilities | 6.57 | -0.38 | -1.79 | -0.65 | 1.09 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.51 | 4.40 | 4.98 | 3.18 | 1.56 |
Net Cash From Operating Activities | -30.89 | -33.82 | -23.04 | -16.31 | -13.27 |
Property & Equipment | -0.58 | -1.01 | -0.21 | -0.21 | -0.07 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 36.78 | 39.04 | -131.24 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 36.20 | 38.15 | -131.45 | -0.21 | -0.07 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.08 | 35.45 | 137.32 | 12.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 |
Net Cash from Financing Activities | 0.00 | 0.08 | 35.45 | 137.31 | 12.08 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 5.31 | 4.40 | -119.04 | 120.79 | -1.26 |
Cash at Beginning of Period | 16.35 | 11.94 | 130.98 | 10.20 | 11.45 |
Cash at End of Period | 21.66 | 16.35 | 11.94 | 130.98 | 10.20 |
Diluted Net EPS | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 |
Fiscal Year End for Cardiff Oncology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -21.79 | -10.01 | -41.44 | -32.10 | -22.37 |
Depreciation/Amortization & Depletion | -0.08 | -0.05 | -0.52 | -0.42 | -0.22 |
Net Change from Assets/Liabilities | 2.59 | 1.20 | 6.57 | 5.18 | 4.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.30 | 1.12 | 4.51 | 3.60 | 2.65 |
Net Cash From Operating Activities | -16.97 | -7.74 | -30.89 | -23.75 | -15.79 |
Property & Equipment | -0.08 | -0.08 | -0.58 | -0.57 | -0.26 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 18.73 | 4.72 | 36.78 | 23.21 | 19.07 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 18.65 | 4.64 | 36.20 | 22.63 | 18.81 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.17 | 0.11 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.17 | 0.11 | 0.00 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 3.85 | -3.00 | 5.31 | -1.11 | 3.02 |
Cash at Beginning of Period | 21.66 | 21.66 | 16.35 | 16.35 | 16.35 |
Cash at End of Period | 25.50 | 18.66 | 21.66 | 15.23 | 19.37 |
Diluted Net EPS | -0.26 | -0.22 | -0.21 | -0.22 | -0.25 |